Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2019716 | 0.83 | MEN1 (0.50) | MEN1KMT2ATDP1MAOATP53 | |
| SCHEMBL13573564 | 0.83 | OPRM1 (0.47) | OPRM1OPRK1TDP1KDM4ECYP3A4 | |
| SCHEMBL29371944 | 0.83 | MEN1 (0.42) | OPRM1OPRK1MEN1KMT2ATDP1 | |
| Hydrochloric Acid SCHEMBL27690675 | 0.81 | MEN1 (0.48) | OPRM1MEN1KMT2ATDP1MAOA | |
| SCHEMBL21193244 | 0.79 | MEN1 (0.45) | MEN1KMT2ATDP1MAOATHRB | |
| SCHEMBL23023065 | 0.79 | MEN1 (0.45) | MEN1KMT2ATDP1MAOAMAPT | |
| SCHEMBL23023165 | 0.76 | MEN1 (0.42) | MEN1KMT2ATDP1MAOATP53 | |
| SCHEMBL23023164 | 0.76 | MEN1 (0.42) | MEN1KMT2ATDP1MAOATP53 | |
| SCHEMBL5028984 | 0.75 | MAOA (0.43) | OPRM1OPRK1MAOATP53GAA | |
| SCHEMBL16269419 | 0.73 | SCN8A (0.43) | OPRM1OPRK1KMT2ATDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332138-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER | VIVOZON, INC. (KR) | 2025-10-30 | — | — | US | disclosed |
| US-12435051-B2 | Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof | VIVOZON, INC. (KR) | 2025-10-07 | — | — | US | disclosed |
| EP-4470534-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER | Vivozon, Inc. (KR) | 2024-12-04 | — | — | EP | disclosed |
| US-20240360092-A1 | DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF | VIVOZON INC. (KR) | 2024-10-31 | — | — | US | disclosed |
| US-12060339-B2 | Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof | VIVOZON INC. (KR) | 2024-08-13 | — | — | US | disclosed |
| EP-4190770-A1 | DUAL REGULATOR FOR MGLUR5 AND 5-HT2A RECEPTORS AND USE THEREOF | Vivozon, Inc. (KR) | 2023-06-07 | — | — | EP | disclosed |
| CN-116234552-A | Dual modulators of mGluR5 and 5-HT2A receptors and uses thereof | (株)倍宝尊 | 2023-06-06 | — | — | CN | disclosed |
| US-20220274939-A1 | DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF | VIVOZON INC. (KR) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435051-B2 | Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof | GRM5, HTR5A, HTR2A | OPRM1 58/4885OPRK1 60/4885MEN1 4816/4885 |
| US-20240360092-A1 | DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF | GRM5, HTR5A, HTR2A | OPRM1 58/4885OPRK1 60/4885MEN1 4816/4885 |
| US-12060339-B2 | Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof | GRM5, HTR5A, HTR2A | OPRM1 58/4885OPRK1 60/4885MEN1 4816/4885 |
| US-20250332138-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER | GRM5, HTR5A, HTR2A | OPRM1 85/4885OPRK1 82/4885MEN1 4437/4885 |
| US-20220274939-A1 | DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF | GRM5, HTR5A, HTR2A | OPRM1 58/4885OPRK1 60/4885MEN1 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.